Edarbyclor is an angiotensin II receptor blocker (ARB) and a thiazide-like diuretic combination product indicated for the treatment of hypertension, to lower blood pressure:
• In patients not adequately controlled with monotherapy
• As initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions

• Renal clearance of lithium is reduced by diuretics, such as chlorthalidone increasing the risk of lithium toxicity
• NSAIDS increase risk of renal dysfunction and interfere with antihypertensive effect

Most common adverse reactions (incidence ≥2%) are dizziness and fatigue.

• In patients with an activated renin-angiotensin-aldosterone system (RAAS), such as volume- and/or salt-depleted patients, Edarbyclor can cause excessive hypotension. Correct volume or salt depletion prior to administration of Edarbyclor
• In patients with renal artery stenosis, Edarbyclor may cause renal failure
• Monitor renal function in patients with renal impairment. Consider discontinuing Edarbyclor with progressive renal impairment